1887

oa SA Pharmaceutical Journal - Exsira® : a newer selective serotonin and noradrenaline reuptake inhibitor for the treatment of depression : new product focus - drug info

Volume 82, Issue 7
  • ISSN : 2221-5875

 

Abstract

Exsira® 50 (100) mg extended-release tablets contain desvenlafaxine 50 mg and 100 mg, and are indicated for the treatment of major depressive disorder (MDD).

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/mp_sapj/82/7/EJC176106
2015-01-01
2017-05-27

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error